US6136301A - Lipid mix for lip product - Google Patents

Lipid mix for lip product Download PDF

Info

Publication number
US6136301A
US6136301A US08/865,821 US86582197A US6136301A US 6136301 A US6136301 A US 6136301A US 86582197 A US86582197 A US 86582197A US 6136301 A US6136301 A US 6136301A
Authority
US
United States
Prior art keywords
formulation
acid
composition
weight
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US08/865,821
Other languages
English (en)
Inventor
Edward Pelle
Kenneth D. Marenus
Christina G. Fthenakis
H. Peter Norden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EL Management LLC
Original Assignee
EL Management LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EL Management LLC filed Critical EL Management LLC
Priority to US08/865,821 priority Critical patent/US6136301A/en
Assigned to E-L MANAGEMENT CORP. reassignment E-L MANAGEMENT CORP. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MARENUS, KENNETH D., FTHENAKIS, CHRISTINA G., NORDEN, H. PETER, PELLE, EDWARD
Priority to EP98304314A priority patent/EP0919225A3/de
Application granted granted Critical
Publication of US6136301A publication Critical patent/US6136301A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37Esters of carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37Esters of carboxylic acids
    • A61K8/375Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63Steroids; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/68Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/001Preparations for care of the lips
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/59Mixtures

Definitions

  • the present invention relates to cosmetic and therapeutic compositions for the lips. More specifically, the invention relates to lip compositions comprising a unique blend of lipids for lip treatment.
  • Skin is typically characterized as consisting of three distinct layers, namely the stratum corneum, the epidermis and the dermis.
  • the stratum corneum the outermost layer, is made up of keratinized cells, surrounded by intercellular space filled with lipids.
  • the stratum corneum provides a substantial physical barrier to penetration of most substances to the lower layers of the skin. In addition to preventing transport of substances to the other skin layers, however, this barrier also aids in prevention of water loss from the skin. Both functions are primarily attributable to the presence of the lipids in the stratum corneum.
  • the skin surface lipids are a diverse group of compounds, comprising triglycerides, diglycerides, ceramides, free fatty acids, wax esters, cholesterol and cholesterol esters, and squalene.
  • the quantity and composition of the skin surface lipids differ from place to place on the body, and may to some extent be related to the number of sebaceous glands in a given area of the skin.
  • the condition of the skin surface lipids may also be affected by an essential fatty acid deficiency.
  • the lipid barrier is easily diminished by exposure to harsh detergents or soaps and other environmental factors. It is apparent, then, that the quality of the skin lipid barrier can vary widely, depending on a number of different factors, and therefore, may not always be adequate to perform its protective function optimally.
  • cosmetic compositions frequently incorporate components which compensate for water loss.
  • examples of such materials are hygroscopic humectants, e.g., urea or propylene glycol; or emollients, e.g., oleyl alcohol or caprylic/capric triglycerides.
  • Certain cosmetic components may be occlusive skin conditioners, which are used to provide an "artificial" barrier; such compounds are frequently hydrophobic materials which remain on the skin surface, and include various hydrogenated oils, waxes and butters.
  • Elias J. Invest. Dermatol. 80(6)Supp.:44, 1983 discloses a naturally-occurring lipid composition, apparently from human abdomen epidermis, containing relatively large quantities of sphingolipids, free sterols, cholesterol sulfate, and free fatty acids.
  • the fatty acids particularly the fatty acid portions of the sphingolipid components, are said to be enriched in long-chain, fully saturated acyl groups.
  • WO 94/00127 further discloses synthetic lipid compositions comprising as its main components cholesterol, ceramides, and fatty acids. Apparently based at least in part on the reported composition of the natural epidermal lipid barrier, these compositions are said to be useful in moisturizing and lipid barrier fortification and repair.
  • lip lipid compositions provide a unique problem, in that, unlike other areas of the body, they are virtually always exposed to seasonal environmental hazards, such as wind, cold and sun, and are therefore susceptible to frequent chapping, cracking and dryness.
  • many lip cosmetics such as traditional lipsticks, may contribute to the dryness.
  • lip products which are aimed at treating or preventing this problem, these are primarily of the "artificial barrier" type, and are not capable of repairing or reconstituting the natural lipid barrier.
  • the present invention provides lipid compositions, useful in cosmetic and therapeutic lip products, which mimic the unique lipid composition of the lips.
  • the lipid compositions comprise, relative to reports of the lipid compositions of the epidermis in other regions of the body, a lipid component containing high levels of cholesteryl esters, and little or no sphingolipid.
  • the amount of cholesteryl ester is at least about 25%, and sphingolipids at an amount of less than 5%.
  • the lipid composition also comprises fatty acids and triglycerides, in amounts of at least about 10%.
  • the lipid compositions of the invention in combination with an appropriate vehicle, can be incorporated into cosmetic products, such as lipsticks, as well as in therapeutic products, such as lip balms.
  • compositions of the invention are useful in repairing a damaged lip lipid barrier or maintaining a healthy lip lipid barrier. Also, the invention relates to a method of treating or preventing damage to the lips, wherein the damage is associated with a reduction or loss of lipid barrier function.
  • the lipid composition of the lips differs from that disclosed for the stratum corneum found on other areas of the body.
  • An analysis of human lip lipids reveals that, unlike other epidermal regions, the lip epidermis contains a relatively high level of cholesteryl esters and only trace amounts of sphingolipids.
  • Elias discloses that stratum corneum from the abdomen contains only about 5% sterol/wax esters, and about 18% sphingolipids, the primary sphingolipids being ceramides.
  • cholesteryl esters represent a very large component, i.e., at least about 25%, of the lip lipid composition.
  • ceramides, or sphingolipids generally, are present in only trace amounts.
  • the lip lipid composition also comprises significant quantities of triglycerides and fatty acids, but in amounts which are not drastically different from those found in regular epidermis.
  • these data make it apparent that lipid compositions designed to mimic the average epidermal lipid barrier will not serve the same function when applied to lips.
  • the knowledge of the composition of the lip lipid barrier makes it possible to design a synthetic lipid composition which can be used to effect lip barrier repair or maintenance, a function not heretofore possible.
  • synthetic as used herein is used solely to distinguish the composition of the invention from the naturally-occurring collection of lipids found in situ on the lips.
  • the lipid composition comprises from about 25 to about 60%, by weight of the total lipid composition, of one or more cholesteryl esters.
  • the cholesteryl ester component constitutes at least 30%, and more preferably, at least 40%, by weight of the total lipid composition.
  • the cholesteryl ester used may be any cholesteryl ester or a mixture of esters; however, analysis of the lip lipid composition indicates that the natural cholesteryl ester component comprises mainly short chain esters.
  • the ester portion of the cholesteryl ester is one or more C 2 -C 16 esters, for example, cholesteryl acetate, cholesteryl butyrate, cholesteryl caprylate, cholesteryl octanoate, cholesteryl decanoate, cholesteryl palmitate or cholesteryl stearate.
  • Particularly preferred are C 2 -C 8 cholesteryl esters.
  • the lipid composition also comprises a glyceride component.
  • glyceride in the present context is meant any compound which is an esterification product of one or more fatty acids and glycerol.
  • the glyceride component may contain one or more mono-, di- or triglycerides, or a mixture thereof. This component is present in an amount of from about 5% to about 40% by weight of the total lipid composition, more preferably about 10-35%.
  • the higher levels of the glyceride are desirable so as to render the composition more compatible with a typically highly hydrophobic wax lipstick base, and also to enhance moisturization.
  • the glyceride component comprises primarily di- and triglycerides, and in a particularly preferred embodiment, the glyceride ester side chains are saturated, so as to hinder potential oxidation.
  • useful glycerides are glyceryl palmitate, glyceryl caprylate, glyceryl myristate, and glyceryl stearate.
  • the lipid composition also contains a free fatty acid component.
  • This component may comprise one or more free fatty acids in an amount of from about 5% to about 40% by weight of the total lipid composition, more preferably from about 10 to about 35%.
  • Any fatty acid can be used; however, it is preferred, for practical purposes, to use fatty acids which are not highly unsaturated, i.e., having two or more unsaturated bonds, so as to avoid the potential for oxidation.
  • useful fatty acids are butyric acid, caproic acid, octanoic acid, decanoic acid, dodecanoic acid, tetradecanoic acid, palmitic acid, stearic acid, and oleic acid.
  • fatty acids with a C 14-18 chain length.
  • a combination of one saturated and one monounsaturated fatty acid is employed.
  • Preferred fatty acids are oleic and palmitic acids, as these are the primary naturally occurring free fatty acids in the stratum corneum.
  • the lipid composition may contain additional optional components as well.
  • Cholesterol is a significant component of the naturally occurring lip lipid composition, and may be added to the mixture in an amount of up to about 25%.
  • small amounts, preferably no more than about 3-10%, of alkene and alkane lipid components may also be included.
  • a particularly distinctive aspect of the preferred lipid compositions of the invention is the low level of sphingolipids, particularly ceramides. Unlike the previously known compositions, the present compositions comprise less than 5%, preferably less than 1%, more preferably less than 0.5%, of a sphingolipid.
  • the lipid mixture comprises cholesteryl esters, glycerides and fatty acids in a weight ratio of about 3:1:1 to about 1:1:1, respectively.
  • the lipid compositions of the present invention are combined with a cosmetically or pharmaceutically acceptable carrier or base.
  • the base may be of any type which is appropriate for use on the lips and around mucous membranes.
  • the vehicle may take the form of creams, lotions, gels, solutions, sprays, and the like.
  • a particularly preferred form of base will be a waxy base, more typically an anhydrous waxy base, as is usual for most products intended for application to the lips. Methods for formulating such wax based products are well known in the art. Briefly, a typical waxy base contains one or more waxes, one or more oils, and one or more surfactants to aid in dispersing the components.
  • Waaxes as used herein intended to comprise not only waxes in the traditional sense, i.e., those plant, animal or mineral waxes containing primarily esters of higher fatty acids and alcohols, free higher acids and alcohols, and saturated hydrocarbons, but also synthetic resinous products having a wax-like, i.e., hard, brittle, relatively non-greasy, texture, such as silicone waxes.
  • suitable waxes for use in the wax base include, but are not limited to, carnauba wax, candelilla wax, beeswax, synthetic wax, shellac wax, spermaceti, lanolin wax, ozokerite, bran wax, ceresin wax, bayberry wax, paraffin, rice wax and jojoba wax.
  • oils as used herein encompass not only naturally occurring plant, animal and mineral oils, but also oil-like emollients, such as fatty esters, fatty alcohols, and silicone oils.
  • the surfactant may be any that is routinely used in this type of product.
  • the lipid component is added to the base in an amount of from about 0.1 to about 60% total lipid, preferably from about 1-20%, more preferably from about 1-10%. It will be apparent that the lipids can be added to the base in the form of a premix, with all the components already combined, or the lipid components can be added to the base individually. Therefore, as used in the present specification and claims, the term "mixture" as applied to the lipid combinations as incorporated in cosmetic or pharmaceutical formulations, will be understood to encompass both a premade mixture, as well as the mixture of the lipids which have been added individually to the formulation.
  • the formulations of the present invention can be used for both cosmetic and pharmaceutical applications.
  • the formulation may take the form of a cosmetic, such as a lipstick or lip gloss, wherein the lipid mixture potentially has both a therapeutic and maintenance effect.
  • the formulation may be completely therapeutic, for example, intended to be used in application to lips which are in need of lipid barrier repair or fortification due to the damaging effects of diseases, chronic or acute conditions, or environmental insult.
  • the formulations also can comprise other components which are chosen depending on the carrier and/or the intended use of the formulation.
  • additional components include, but are not limited to, water soluble colorants (such as FD&C Blue #1); oil soluble colorants (such as D&C Green #6); water soluble sunscreens (such as Eusolex 232); oil soluble sunscreens (such as Octyl Methoxycinnamate); particulate sunscreens (such as Zinc Oxide); antioxidants (such as BHT); chelating agents (such as Disodium EDTA); emulsion stabilizers (such as carbomer); preservatives (such as Methyl Paraben); fragrances (such as pinene); emollients (such as petrolatum); flavoring agents (such as sorbitol); humectants (such as glycerine); waterproofing agents (such as PVP/Eicosene Copolymer); water soluble film-formers (such as Hydroxypropyl methylcellulose); oil-soluble film formers (such as Hydrogenated C-9 Resin); cationic polymers (such as Polyquaternium
  • the therapeutic effect of the lipid mixture may be particularly desirable to combine the therapeutic effect of the lipid mixture with other active components intended for therapeutic treatment of the lip area.
  • actives include antiinflammatories, antihistamines, antiirritants, antibiotics, antivirals, antifungals, and antipruritics.
  • conditions which can benefit from application of such combinations include, but are not limited to, ulcers, blisters, herpes virus infections, severe chapping, or burns.
  • Methods and/or regimens for application of the lip products of the invention are in accordance with the normal usage of products of similar type, i.e., lipsticks, lip balms, ointments, etc.. Additional uses of the formulations of the invention will be readily apparent to those skilled in the art.
  • This example describes analysis of the lipid content of human facial lips:
  • a 9 mm diameter polypropylene cup is held firmly on the lip. This is followed by washing of the lip with 0.5 ml of solvent, either ethanol or hexane. The washing step is repeated on another area of lip and the two washes pooled, taken to dryness and resuspended in 50 ml of chloroform.
  • Varying amounts of the resuspended material are spotted onto TLC plates and chromatographed according to Melnick et al.(J. Invest. Dermatol. 92:231, 1989). Lipids are then visualized by acid treatment and charring. They are identified by their mobility on the plate to those of known standards with a densitometer. Similarly, their concentrations are determined by their absorption as compared to the same standards.
  • the components found in an ethanol extraction are shown below. From this plate, cholesterol, fatty acids, triglycerides, cholesteryl esters, and squalene can be identified. Possibly, there are traces of cholesterol sulfate and ceramide (not III or IV). In addition, when hexane is used as solvent, alkanes are also observable in trace amounts.
  • the primary components of the extract are as follows:
  • a lipid mixture of the invention is prepared as follows:
  • a lipstick containing 1% of the lipid mixture is prepared, and used to determine the efficacy of the final product in moisturizing treated lips.
  • Evaluation of lip flakiness is carried out by the D-squame Disc Method, and Image Analysis Evaluation. Specifically, samples are collected on D-Squame discs, two from the top lip and two from the bottom lip. the discs are place on the lips slightly overlapping, pressed firmly and the D-Squame discs are then peeled off. The discs are mounted on clear glass slides and evaluated by image analysis.
  • the imaging parameter analyzed for the evaluation of the lip D-Squame samples is the Integrated Optical Density (IOD), which is defined as the total amount(area)of the D-Squames X the D-Squame density (255-Mn Gray Value).
  • IOD Integrated Optical Density
  • a reduction in IOD represents smoother, less flaky lips.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
US08/865,821 1997-05-30 1997-05-30 Lipid mix for lip product Expired - Lifetime US6136301A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US08/865,821 US6136301A (en) 1997-05-30 1997-05-30 Lipid mix for lip product
EP98304314A EP0919225A3 (de) 1997-05-30 1998-06-01 Lipidmischung für auf die Lippen

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/865,821 US6136301A (en) 1997-05-30 1997-05-30 Lipid mix for lip product

Publications (1)

Publication Number Publication Date
US6136301A true US6136301A (en) 2000-10-24

Family

ID=25346311

Family Applications (1)

Application Number Title Priority Date Filing Date
US08/865,821 Expired - Lifetime US6136301A (en) 1997-05-30 1997-05-30 Lipid mix for lip product

Country Status (2)

Country Link
US (1) US6136301A (de)
EP (1) EP0919225A3 (de)

Cited By (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6432428B1 (en) * 1997-10-17 2002-08-13 International Flora Technologies Dry emollient composition composing mono-unsaturated jojoba esters
US20030161851A1 (en) * 2002-02-14 2003-08-28 Bonne Bell, Inc. Cosmetic lip product with sour flavor
US6723307B2 (en) 2002-02-14 2004-04-20 Bonne Bell, Inc. Cosmetic lip product with sour flavor
US20050196461A1 (en) * 2004-01-14 2005-09-08 Udell Ronald G. Ceramide formulations suitable for oral administration
US20050260291A1 (en) * 2004-03-10 2005-11-24 Palu Afa K Methods and compositions for reactivating acetylcholinesterase
US20060141076A1 (en) * 2004-11-01 2006-06-29 Palu Afa K Morinda citrifolia based compositions and methods for inhibiting xanthine oxidase
US20060159788A1 (en) * 2002-11-14 2006-07-20 Brett West Method and formulation for treating Candidiasis using Morinda citrifolia
US20060193932A1 (en) * 2001-11-02 2006-08-31 Jensen Claude J Morinda citrifolia enhanced colon cancer cell growth inhibitor
US20060269630A1 (en) * 2003-04-16 2006-11-30 Palu Afa K Morinda citrifolia as a 5-Lipoxygenase inhibitor
US20060269631A1 (en) * 2003-05-02 2006-11-30 Chen Su Morinda citrifolia-based formulation for inhibiting metastasis of carcinogenic cells
US20060275359A1 (en) * 2001-04-17 2006-12-07 Jensen Claude J Palliative effects of morinda citrifolia oil and juice
US20060280818A1 (en) * 2005-05-26 2006-12-14 Palu Afa K Nicotinic acetylcholine receptor antagonist
US20070087108A1 (en) * 2005-10-18 2007-04-19 Wadsworth John W Garcinia mangostana L. enhanced animal food product
US20070087066A1 (en) * 2002-05-21 2007-04-19 Scott Gerson Antifungal effects of Morinda citrifolia
US20070122507A1 (en) * 2005-05-26 2007-05-31 Palu Afa K Histone deacetylase and tumor necrosis factor converting enzyme inhibition
US20070154582A1 (en) * 2003-03-25 2007-07-05 Palu Afa K Preventative and Treatment Effects of Morinda Citrifolia as an Aromatase Inhibitor
US20070166416A1 (en) * 2005-03-09 2007-07-19 Palu Afa K Formulations and Methods for Preventing and Treating Substance Abuse and Addiction
US20070178181A1 (en) * 2001-11-02 2007-08-02 Jensen Claude J Preventative and treatment effects of morinda citrifolia on diabetes and its related conditions
US20070196527A1 (en) * 2006-02-23 2007-08-23 Jensen Claude J Preventative and treatment effects of Morinda citrifolia on Osteoarthritis and its related conditions
US20070204510A1 (en) * 2003-06-03 2007-09-06 Fumiyuki Isami Fertilizer Containing Yaeyama Aoki Extract
US20070218146A1 (en) * 2004-01-15 2007-09-20 Palu Afa K Lipoxygenase and cyclooxygenase inhibition
US20070237848A1 (en) * 2005-12-21 2007-10-11 Brad Rawson MORINDA CITRIFOLIA BASED COMPOSITIONS FOR TREATMENT OF ANTI-INFLAMMATORY DISEASES THROUGH INHIBITION OF COX-1, COX-2, INTERLEUKIN-1beta, INTERLEUKIN-6, TNF-alpha, HLE, AND iNOS
US20070259060A1 (en) * 2003-08-12 2007-11-08 Mian-Ying Wang Formulations and Methods for Treating Breast Cancer with Morinda Citrifolia and Methylsulfonymethane
US20070281903A1 (en) * 2006-05-04 2007-12-06 Palu Afa K Morinda Citrifolia-Based Formulation 5-LOX And 15-LOX
US20080206367A1 (en) * 2004-09-01 2008-08-28 Sid Liu Morinda Citrifolia-based Formulations and Methods for Weight Management
US20080213415A1 (en) * 2007-02-08 2008-09-04 Palu Afa K Treatment of Glaucoma and Diabetic Retinopathy with Morinda Citrifolia Enhanced Formulations
US20080226758A1 (en) * 2006-11-28 2008-09-18 Shixin Deng Lipoxygenase and Cyclooxygenase Inhibition
US20080317890A1 (en) * 2007-06-21 2008-12-25 Claude Jarakae Jensen Method for treating visual impairment through the prophylactic administration of a morinda citrifolia-based naturaceutical
US20090196944A1 (en) * 2008-02-01 2009-08-06 Brad Rawson Methods of Manufacture of Morinda Citrifolia Based Compositions for Treatment of Anti-Inflammatory Diseases through Inhibition of Cox-1, Cox-2, Interleukin -1beta, Interleukin-6, TNF-alpha, HLE, and iNOS
US20110135746A1 (en) * 2009-12-09 2011-06-09 Triplett Janice L Protective lip balm composition
US20110160057A1 (en) * 2001-11-14 2011-06-30 Bryant Wadsworth Morinda Citrifolia Based Antimicrobial Formulations
US20110171333A1 (en) * 2000-12-05 2011-07-14 Bryant Wadsworth Morinda Citrifolia Based Antioxidant and Antimicrobial Formulations for Improved Color Stability and Increased Shelf Life of Various Meat Products
US20110206787A1 (en) * 2000-12-05 2011-08-25 Brett Justin West Morinda Citrifolia and Iridoid Based Formulations
US20110206786A1 (en) * 2010-02-23 2011-08-25 Brett Justin West Acai and Iridoid Based Formulations
US20110217394A1 (en) * 2000-12-05 2011-09-08 Brett Justin West Iridoid Based Formulations
US8025910B2 (en) 2006-05-12 2011-09-27 Tahitian Noni International, Inc. Method and composition for administering bioactive compounds derived from Morinda citrifolia
US8535741B2 (en) 2006-05-12 2013-09-17 Morinda, Inc. Method and composition for administering bioactive compounds derived from Morinda citrifolia
US8574642B2 (en) 2000-12-05 2013-11-05 Tahitian Noni International, Inc. Antiviral Morinda citrifolia L. based formulations and methods of administration
US8652546B2 (en) 2007-09-06 2014-02-18 Tahitian Noni International, Inc. Morinda citrifolia based formulations for regulating T cell immunomodulation in neonatal stock animals
US20150196482A1 (en) * 2014-01-10 2015-07-16 James Robert Bleyer Compositions of cosmetic, personal care and skin care products derived from lipid feedstocks and methods to produce the same

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1317890B1 (it) * 2000-08-03 2003-07-15 Idi Irccs Preparato da utilizzare come componente lipidico nei cosmetici.
FR2831442B1 (fr) * 2001-10-30 2005-02-11 Oreal Composition cosmetique mimant le sebum, et utilisations
KR20060134913A (ko) * 2003-09-10 2006-12-28 이스트만 케미칼 컴파니 피토리피드 조성물의 회수 방법
US7416756B2 (en) 2003-09-10 2008-08-26 Eastman Chemical Company Process for the recovery of a phytolipid composition
US7695727B2 (en) 2006-10-11 2010-04-13 Wyeth Llc Botanical butter stick lip balm

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1477048A (fr) * 1965-04-23 1967-04-14 Oreal Nouveaux agents tensio-actifs non ioniques et leur procédé de préparation
US3821372A (en) * 1970-05-12 1974-06-28 Oreal Emulsion containing oil,water and as emulsifier the polycondensation product of glycidol on alpha diols with fatty chain
US3928224A (en) * 1970-05-12 1975-12-23 Oreal Shampoo composition obtained from the polycondensation of glycidol on alpha diols with fatty chain with alkaline catalysts
US4087466A (en) * 1970-05-12 1978-05-02 L'oreal Polycondensation of glycidol on alpha diols with fatty chain with alkaline catalysts, products thus obtained and utilization
GB1539625A (en) * 1975-06-30 1979-01-31 Oreal Process for preparing aqueous dispersions of lipid spherules and aqueous dispersions of such lipid spherules
WO1983001571A1 (en) * 1981-10-29 1983-05-11 Univ California Liposome conjugates and diagnostic methods therewith
US4610868A (en) * 1984-03-20 1986-09-09 The Liposome Company, Inc. Lipid matrix carriers for use in drug delivery systems
US5053229A (en) * 1985-07-31 1991-10-01 Kao Corporation Cosmetic compositions
WO1994000127A1 (en) * 1992-06-19 1994-01-06 The Regents Of The University Of California Lipids for epidermal moisturization and repair of barrier function
US5618523A (en) * 1991-02-21 1997-04-08 L'oreal Ceramides, process for their preparation and their applications in the cosmetic and dermopharmaceutical fields

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2627385B3 (fr) * 1988-02-23 1991-08-23 Serobiologiques Lab Sa Composition notamment utile comme matiere de base pour la preparation de compositions pharmaceutiques, notamment dermatologiques et/ou cosmetiques

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1477048A (fr) * 1965-04-23 1967-04-14 Oreal Nouveaux agents tensio-actifs non ioniques et leur procédé de préparation
US3821372A (en) * 1970-05-12 1974-06-28 Oreal Emulsion containing oil,water and as emulsifier the polycondensation product of glycidol on alpha diols with fatty chain
US3928224A (en) * 1970-05-12 1975-12-23 Oreal Shampoo composition obtained from the polycondensation of glycidol on alpha diols with fatty chain with alkaline catalysts
US4087466A (en) * 1970-05-12 1978-05-02 L'oreal Polycondensation of glycidol on alpha diols with fatty chain with alkaline catalysts, products thus obtained and utilization
GB1539625A (en) * 1975-06-30 1979-01-31 Oreal Process for preparing aqueous dispersions of lipid spherules and aqueous dispersions of such lipid spherules
WO1983001571A1 (en) * 1981-10-29 1983-05-11 Univ California Liposome conjugates and diagnostic methods therewith
US4610868A (en) * 1984-03-20 1986-09-09 The Liposome Company, Inc. Lipid matrix carriers for use in drug delivery systems
US5053229A (en) * 1985-07-31 1991-10-01 Kao Corporation Cosmetic compositions
US5618523A (en) * 1991-02-21 1997-04-08 L'oreal Ceramides, process for their preparation and their applications in the cosmetic and dermopharmaceutical fields
WO1994000127A1 (en) * 1992-06-19 1994-01-06 The Regents Of The University Of California Lipids for epidermal moisturization and repair of barrier function

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
Elias, P. M. (Ed.), "Advances in Lipid Research, vol. 24, Skin Lipids", pp. 1-56 (Academic Press, Inc., 1991).
Elias, P. M. (Ed.), Advances in Lipid Research, vol. 24, Skin Lipids , pp. 1 56 (Academic Press, Inc., 1991). *
Peter M. Elias, M.D., Epidermal Lipids, Barrier Function, and Desquamation, J. Invest. Dermatol. 80 (6) Supp.: 44, 1983. *
Peter M. Elias, M.D., Epidermal Lipids, Barrier Function, and Desquamation,-J. Invest. Dermatol. 80 (6) Supp.: 44, 1983.
Scanu, A. M., Spector, A. A. (Eds.), "Biochemistry and Biology of Plasma Lipoproteins", pp. 223-245 (Marcel Dekker, Inc. 1985).
Scanu, A. M., Spector, A. A. (Eds.), Biochemistry and Biology of Plasma Lipoproteins , pp. 223 245 (Marcel Dekker, Inc. 1985). *
Strauss, J. F., Menon, K. M. J., "Lipoprotein and Cholesterol Metabolism in Steroidogenic Tissues", pp. 1-32 (George F. Stickley Company, 1985).
Strauss, J. F., Menon, K. M. J., Lipoprotein and Cholesterol Metabolism in Steroidogenic Tissues , pp. 1 32 (George F. Stickley Company, 1985). *

Cited By (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6432428B1 (en) * 1997-10-17 2002-08-13 International Flora Technologies Dry emollient composition composing mono-unsaturated jojoba esters
US20110171333A1 (en) * 2000-12-05 2011-07-14 Bryant Wadsworth Morinda Citrifolia Based Antioxidant and Antimicrobial Formulations for Improved Color Stability and Increased Shelf Life of Various Meat Products
US20110206787A1 (en) * 2000-12-05 2011-08-25 Brett Justin West Morinda Citrifolia and Iridoid Based Formulations
US20110217394A1 (en) * 2000-12-05 2011-09-08 Brett Justin West Iridoid Based Formulations
US8574642B2 (en) 2000-12-05 2013-11-05 Tahitian Noni International, Inc. Antiviral Morinda citrifolia L. based formulations and methods of administration
US8790727B2 (en) 2000-12-05 2014-07-29 Tahitian Noni International, Inc. Morinda citrifolia and iridoid based formulations
US20060275359A1 (en) * 2001-04-17 2006-12-07 Jensen Claude J Palliative effects of morinda citrifolia oil and juice
US20060193932A1 (en) * 2001-11-02 2006-08-31 Jensen Claude J Morinda citrifolia enhanced colon cancer cell growth inhibitor
US20070178181A1 (en) * 2001-11-02 2007-08-02 Jensen Claude J Preventative and treatment effects of morinda citrifolia on diabetes and its related conditions
US20090053336A1 (en) * 2001-11-14 2009-02-26 Brett West Method and Formulations for Treating Candidiasis Using Morinda Citrifolia
US20110160057A1 (en) * 2001-11-14 2011-06-30 Bryant Wadsworth Morinda Citrifolia Based Antimicrobial Formulations
US20030161851A1 (en) * 2002-02-14 2003-08-28 Bonne Bell, Inc. Cosmetic lip product with sour flavor
US6723307B2 (en) 2002-02-14 2004-04-20 Bonne Bell, Inc. Cosmetic lip product with sour flavor
US20070087066A1 (en) * 2002-05-21 2007-04-19 Scott Gerson Antifungal effects of Morinda citrifolia
US7442395B2 (en) 2002-11-14 2008-10-28 Tahitian Noni International, Inc. Formulation for treating candidiasis using Morinda citrifolia
US20060159788A1 (en) * 2002-11-14 2006-07-20 Brett West Method and formulation for treating Candidiasis using Morinda citrifolia
US20070154582A1 (en) * 2003-03-25 2007-07-05 Palu Afa K Preventative and Treatment Effects of Morinda Citrifolia as an Aromatase Inhibitor
US20060269630A1 (en) * 2003-04-16 2006-11-30 Palu Afa K Morinda citrifolia as a 5-Lipoxygenase inhibitor
US20060269631A1 (en) * 2003-05-02 2006-11-30 Chen Su Morinda citrifolia-based formulation for inhibiting metastasis of carcinogenic cells
US20070204510A1 (en) * 2003-06-03 2007-09-06 Fumiyuki Isami Fertilizer Containing Yaeyama Aoki Extract
US20070259060A1 (en) * 2003-08-12 2007-11-08 Mian-Ying Wang Formulations and Methods for Treating Breast Cancer with Morinda Citrifolia and Methylsulfonymethane
US20050196461A1 (en) * 2004-01-14 2005-09-08 Udell Ronald G. Ceramide formulations suitable for oral administration
US20070218146A1 (en) * 2004-01-15 2007-09-20 Palu Afa K Lipoxygenase and cyclooxygenase inhibition
US20050260291A1 (en) * 2004-03-10 2005-11-24 Palu Afa K Methods and compositions for reactivating acetylcholinesterase
US20070160700A1 (en) * 2004-03-10 2007-07-12 Palu Afa K Methods and compositions for reactivating acetylcholinesterase
US20080206367A1 (en) * 2004-09-01 2008-08-28 Sid Liu Morinda Citrifolia-based Formulations and Methods for Weight Management
US20060141076A1 (en) * 2004-11-01 2006-06-29 Palu Afa K Morinda citrifolia based compositions and methods for inhibiting xanthine oxidase
US20070166416A1 (en) * 2005-03-09 2007-07-19 Palu Afa K Formulations and Methods for Preventing and Treating Substance Abuse and Addiction
US20060280818A1 (en) * 2005-05-26 2006-12-14 Palu Afa K Nicotinic acetylcholine receptor antagonist
US20070122507A1 (en) * 2005-05-26 2007-05-31 Palu Afa K Histone deacetylase and tumor necrosis factor converting enzyme inhibition
US20070087108A1 (en) * 2005-10-18 2007-04-19 Wadsworth John W Garcinia mangostana L. enhanced animal food product
US7244463B2 (en) 2005-10-18 2007-07-17 Tahitian Noni International, Inc. Garcinia mangostana L. enhanced animal food product
US20070237848A1 (en) * 2005-12-21 2007-10-11 Brad Rawson MORINDA CITRIFOLIA BASED COMPOSITIONS FOR TREATMENT OF ANTI-INFLAMMATORY DISEASES THROUGH INHIBITION OF COX-1, COX-2, INTERLEUKIN-1beta, INTERLEUKIN-6, TNF-alpha, HLE, AND iNOS
US20070196527A1 (en) * 2006-02-23 2007-08-23 Jensen Claude J Preventative and treatment effects of Morinda citrifolia on Osteoarthritis and its related conditions
US20070281903A1 (en) * 2006-05-04 2007-12-06 Palu Afa K Morinda Citrifolia-Based Formulation 5-LOX And 15-LOX
US8025910B2 (en) 2006-05-12 2011-09-27 Tahitian Noni International, Inc. Method and composition for administering bioactive compounds derived from Morinda citrifolia
US8535741B2 (en) 2006-05-12 2013-09-17 Morinda, Inc. Method and composition for administering bioactive compounds derived from Morinda citrifolia
US20080226758A1 (en) * 2006-11-28 2008-09-18 Shixin Deng Lipoxygenase and Cyclooxygenase Inhibition
US20080213415A1 (en) * 2007-02-08 2008-09-04 Palu Afa K Treatment of Glaucoma and Diabetic Retinopathy with Morinda Citrifolia Enhanced Formulations
US20080317890A1 (en) * 2007-06-21 2008-12-25 Claude Jarakae Jensen Method for treating visual impairment through the prophylactic administration of a morinda citrifolia-based naturaceutical
US8652546B2 (en) 2007-09-06 2014-02-18 Tahitian Noni International, Inc. Morinda citrifolia based formulations for regulating T cell immunomodulation in neonatal stock animals
US20090196944A1 (en) * 2008-02-01 2009-08-06 Brad Rawson Methods of Manufacture of Morinda Citrifolia Based Compositions for Treatment of Anti-Inflammatory Diseases through Inhibition of Cox-1, Cox-2, Interleukin -1beta, Interleukin-6, TNF-alpha, HLE, and iNOS
US20110135746A1 (en) * 2009-12-09 2011-06-09 Triplett Janice L Protective lip balm composition
US20110206786A1 (en) * 2010-02-23 2011-08-25 Brett Justin West Acai and Iridoid Based Formulations
US20150196482A1 (en) * 2014-01-10 2015-07-16 James Robert Bleyer Compositions of cosmetic, personal care and skin care products derived from lipid feedstocks and methods to produce the same
US9889084B2 (en) * 2014-01-10 2018-02-13 Valicor, Inc. Compositions of cosmetic, personal care and skin care products derived from lipid feedstocks and methods to produce the same

Also Published As

Publication number Publication date
EP0919225A2 (de) 1999-06-02
EP0919225A3 (de) 2000-12-20

Similar Documents

Publication Publication Date Title
US6136301A (en) Lipid mix for lip product
AU681805B2 (en) Product for topical application containing a lipase and an active ingredient precursor
EP1032363B1 (de) Konjugierte linolsäure enthaltendes verteilungssystem in kosmetika
KR100519638B1 (ko) 지질 장벽 합성을 강화시키는 조성물 및 그 방법
EP0709084B1 (de) Verwendung eines an Petroselinsäurereichen Öls als Feuchthaltemittel
US5741496A (en) Process for the treatment of skins having dry areas and greasy areas
JP2009143952A (ja) 生酵母細胞誘導体を含有するリップトリートメント
US5928659A (en) Cosmetic formulation and method for amelioration of skin keratoses and striae distensae
JPH1087476A (ja) ヒドロキシ酸またはレチノイドを含有する組成物中の刺激防止剤としてのルリヂサ種子油
CA2072805A1 (en) Cosmetic stick
US5759555A (en) Cosmetic formulation and method for amelioration of skin keratoses and striae distensae
US20050244359A1 (en) Topical regulation of triglyceride metabolism
US6716437B1 (en) Topical composition and method for enhancing lipid barrier synthesis
KR100858626B1 (ko) 세라마이드 및 합성 팔미토일펜타펩타이드를 유효성분으로함유하는 입술 보호용 화장료 조성물
KR100262176B1 (ko) 레티노이드를함유한스틱형입술화장료조성물
JP2025514734A (ja) 皮膚バリア保護送達システムおよびその方法

Legal Events

Date Code Title Description
AS Assignment

Owner name: E-L MANAGEMENT CORP., NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PELLE, EDWARD;MARENUS, KENNETH D.;FTHENAKIS, CHRISTINA G.;AND OTHERS;REEL/FRAME:008880/0519;SIGNING DATES FROM 19970603 TO 19970604

STCF Information on status: patent grant

Free format text: PATENTED CASE

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

FPAY Fee payment

Year of fee payment: 12